EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

C3 glomerulopathy: Understanding an ultra‐rare complement‐mediated renal disease

Amanda K Heiderscheit iD, Jill J Hauer iD, Richard J H Smith

American Journal of Medical Genetics Part C: Seminars in Medical Genetics · 2022-09 · 190 (3) · 344-357

DOI: 10.1002/ajmg.c.31986 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift American Journal of Medical Genetics Part C: Seminars in Medical Genetics, online erschienen am 23.06.2022. Verfasst von Amanda K Heiderscheit und 2 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Otolaryngology and Renal Research Laboratories, Carver College of Medicine, University of Iowa, Iowa City, Iowa, USA. Hauptthemen laut MEDLINE: Glomerulonephritis, Membranoproliferative, Kidney Diseases. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDDK NIH HHS, NHLBI NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

C3 glomerulopathy (C3G) describes a pathologic pattern of injury diagnosed by renal biopsy. It is characterized by the dominant deposition of the third component of complement (C3) in the renal glomerulus as resolved by immunofluorescence microscopy. The underlying pathophysiology is driven by dysregulation of the alternative pathway of complement in the fluid‐phase and in the glomerular microenvironment. Characterization of clinical features and a targeted evaluation for indices and drivers of complement dysregulation are necessary for optimal patient care. Autoantibodies to the C3 and C5 convertases of complement are the most commonly detected drivers of complement dysregulation, although genetic mutations in complement genes can also be found. Approximately half of patients progress to end‐stage renal disease within 10 years of diagnosis, and, while transplantation is a viable option, there is high risk for disease recurrence and allograft failure. This poor outcome reflects the lack of disease‐specific therapy for C3G, relegating patients to symptomatic treatment to minimize proteinuria and suppress renal inflammation. Fortunately, the future is bright as several anti‐complement drugs are currently in clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glomerulonephritis, MembranoproliferativeKidney DiseasesHumansKidneyRare Diseases

Stichwörter der Autor:innen

C3 glomerulonephritisC3 glomerulopathydense deposit disease

Autor:innen und Institutionen

  • Molecular Otolaryngology and Renal Research Laboratories, Carver College of Medicine, University of Iowa, Iowa City, Iowa, USA.
  • Graduate PhD Program in Immunology, Carver College of Medicine, University of Iowa, Iowa City, Iowa, USA.

ORCID-Profile: Amanda K Heiderscheit, Jill J Hauer

Förderung

  • NIDDK NIH HHS
  • NHLBI NIH HHS
  • National Institutes of Health

Zitieren

APA

Heiderscheit, A. K., Hauer, J. J., & Smith, R. J. H. (2022). C3 glomerulopathy: Understanding an ultra‐rare complement‐mediated renal disease. American Journal of Medical Genetics Part C: Seminars in Medical Genetics, 190(3), 344-357. https://doi.org/10.1002/ajmg.c.31986

Vancouver

Heiderscheit AK, Hauer JJ, Smith RJH. C3 glomerulopathy: Understanding an ultra‐rare complement‐mediated renal disease. American Journal of Medical Genetics Part C: Seminars in Medical Genetics. 2022;190(3):344-357. doi:10.1002/ajmg.c.31986

BibTeX
@article{Heiderscheit2022,
  author = {Heiderscheit, Amanda K and Hauer, Jill J and Smith, Richard J H},
  title = {C3 glomerulopathy: Understanding an ultra‐rare complement‐mediated renal disease},
  journal = {American Journal of Medical Genetics Part C: Seminars in Medical Genetics},
  year = {2022},
  volume = {190},
  number = {3},
  pages = {344--357},
  doi = {10.1002/ajmg.c.31986}
}
Kostenlos starten →